Join

Compare · IMRA vs RVMD

IMRA vs RVMD

Side-by-side comparison of IMARA Inc. (IMRA) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both IMRA and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • RVMD is the larger of the two at $45.31B, about 1249.5x IMRA ($36.3M).
  • Over the past year, IMRA is down 61.2% and RVMD is up 466.1% - RVMD leads by 527.3 points.
  • RVMD has hit the wire 11 times in the past 4 weeks while IMRA has been quiet.
  • RVMD has more recent analyst coverage (25 ratings vs 3 for IMRA).
PerformanceIMRA-61.22%RVMD+384.87%
2025-08-26+0.00%2026-07-31
MetricIMRARVMD
Company
IMARA Inc.
Revolution Medicines Inc.
Price
-
-
Market cap
$36.3M
$45.31B
1M return
-12.59%
+12.27%
1Y return
-61.22%
+466.09%
Sector
Health Care
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2020
2020
News (4w)
0
11
Recent ratings
3
25
IMRA

IMARA Inc.

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

RVMD

Revolution Medicines Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.

Latest IMRA

Latest RVMD